Polymorphisms at the microRNA binding-site of the stem cell marker gene CD133 modify susceptibility to and survival of gastric cancer

Molecular Carcinogenesis

Volumn 54, Issue 6, 2015, Pages 449-458

  Wang, Qiming ^a,b   Liu, Hongliang ^b   Xiong, Huihua ^b   Liu, Zhensheng ^b   Wang, Li E ^b   Qian, Ji ^b   Muddasani, Ramya ^b   Lu, Victoria ^b   Tan, Dongfeng ^b   Ajani, Jaffer A ^b   Wei, Qingyi ^b,c  

^a ZHENGZHOU UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c DUKE CANCER INSTITUTE   (United States)

Author keywords

Gastric cancer; MicroRNA; Polymorphism; Stem cell; Survival

Indexed keywords

BIOLOGICAL MARKER; CD133 ANTIGEN; MICRORNA; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; PEPTIDE;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; BINDING SITE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CASE CONTROL STUDY; CONTROLLED STUDY; ETHNICITY; FAMILY HISTORY; FEMALE; FOLLOW UP; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HAPLOTYPE; HELICOBACTER INFECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; STOMACH CANCER; TOBACCO USE; GENETIC PREDISPOSITION; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; STOMACH; STOMACH NEOPLASMS; SURVIVAL;

ANTIGENS, CD; CASE-CONTROL STUDIES; GENETIC PREDISPOSITION TO DISEASE; GLYCOPROTEINS; HUMANS; MICRORNAS; MIDDLE AGED; PEPTIDES; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; STOMACH; STOMACH NEOPLASMS; SURVIVAL ANALYSIS;

EID: 84927007002     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.22113     Document Type: Article

References (41)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74-108.
2. Helicobacter and Cancer Collaborative Group. Gastric cancer and Helicobacter pylori: A combined analysis of 12 case control studies nested within prospective cohorts. Gut 2001; 49:347-353.
3. Tramacere I, Negri E, Pelucchi C, et al. A meta-analysis on alcohol drinking and gastric cancer risk. Ann Oncol 2012; 23:28-36.
4. Gonzalez CA, Agudo A. Carcinogenesis, prevention and early detection of gastric cancer: Where we are and where we should go. Int J Cancer 2012; 130:745-753.
5. Yaghoobi M, Bijarchi R, Narod SA. Family history and the risk of gastric cancer. Br J Cancer 2010; 102:237-242.
6. Higuchi K, Tanabe S, Azuma M, Sasaki T, Ishido K, Koizumi W. Future perspectives for the development of chemotherapy for advanced gastric cancer: Japanese and global status. Pathobiology 2011; 78:334-342.
7. Kim CF, Dirks PB. Cancer and stem cell biology: How tightly intertwined? Cell Stem Cell 2008; 3:147-150.
8. Yu X, Lin Y, Yan X, Tian Q, Li L, Lin EH. CD133, stem cells, and cancer stem cells: Myth or reality? Curr Colorectal Cancer Rep 2011; 7:253-259.
9. Chung CC, Chanock SJ. Current status of genome-wide association studies in cancer. Hum Genet 2011; 130:59-78.
10. Sakamoto H, Yoshimura K, Saeki N, et al. Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer. Nat Genet 2008; 40:730-740.
11. Wu C, Wang G, Yang M, et al. Two genetic variants in prostate stem cell antigen and gastric cancer susceptibility in a Chinese population. Mol Carcinog 2009; 48:1131-1138.
12. Sala N, Munoz X, Travier N, et al. Prostate stem-cell antigen gene is associated with diffuse and intestinal gastric cancer in Caucasians: Results from the EPIC-EURGAST study. Int J Cancer 2012; 130:2417-2427.
13. Wang M, Bai J, Tan Y, et al. Genetic variant in PSCA predicts survival of diffuse-type gastric cancer in a Chinese population. Int J Cancer 2011; 129:1207-1213.
14. Cheng M, Yang L, Yang R, et al. A microRNA-135a/b binding polymorphism in CD133 confers decreased risk and favorable prognosis of lung cancer in Chinese by reducing CD133 expression. Carcinogenesis 2013; 34:2292-2299.
15. Pohl A, El-Khoueiry A, Yang D, et al. Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy. Pharmacogenomics J 2013; 13:173-180.
16. Liu Z, Wei S, Ma H, et al. A functional variant at the miR-184 binding site in TNFAIP2 and risk of squamous cell carcinoma of the head and neck. Carcinogenesis 2011; 32:1668-1674.
17. Dick JE. Future prospects for animal models created by transplanting human haematopoietic cells into immune-deficient mice. Res Immunol 1994; 145:380-384.
18. Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science 2011; 331:1559-1564.
19. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100:3983-3988.
20. Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003; 63:5821-5828.
21. Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994; 367:645-648.
22. Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007; 445:111-115.
23. Li C, Heidt DG, Dalerba P, et al. Identification of pancreatic cancer stem cells. Cancer Res 2007; 67:1030-1037.
24. Kim CF, Jackson EL, Woolfenden AE, et al. Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 2005; 121:823-835.
25. Wu PC, Lai VC, Fang JW, Gerber MA, Lai CL, Lau JY. Hepatocellular carcinoma expressing both hepatocellular and biliary markers also expresses cytokeratin 14, a marker of bipotential progenitor cells. J Hepatol 1999; 31:965-966.
26. Schatton T, Murphy GF, Frank NY, et al. Identification of cells initiating human melanomas. Nature 2008; 451:345-349.
27. Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, et al. Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. Proc Natl Acad Sci USA 2006; 103:11154-11159.
28. Chan KS, Espinosa I, Chao M, et al. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc Natl Acad Sci USA 2009; 106:14016-14021.
29. Prince ME, Sivanandan R, Kaczorowski A, et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA 2007; 104:973-978.
30. Takaishi S, Okumura T, Tu S, et al. Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells 2009; 27:1006-1020.
31. Fukuda K, Saikawa Y, Ohashi M, et al. Tumor initiating potential of side population cells in human gastric cancer. Int J Oncol 2009; 34:1201-1207.
32. Corbeil D, Roper K, Fargeas CA, Joester A, Huttner WB. Prominin: A story of cholesterol, plasma membrane protrusions and human pathology. Traffic 2001; 2:82-91.
33. Zhao P, Li Y, Lu Y. Aberrant expression of CD133 protein correlates with Ki-67 expression and is a prognostic marker in gastric adenocarcinoma. BMC Cancer 2010; 10:218.
34. Ishigami S, Ueno S, Arigami T, et al. Prognostic impact of CD133 expression in gastric carcinoma. Anticancer Res 2010; 30:2453-2457.
35. Rocco A, Liguori E, Pirozzi G, et al. CD133 and CD44 cell surface markers do not identify cancer stem cells in primary human gastric tumors. J Cell Physiol 2012; 227:2686-2693.
36. Yu JW, Zhang P, Wu JG, et al. Expressions and clinical significances of CD133 protein and CD133 mRNA in primary lesion of gastric adenocacinoma. J Exp Clin Cancer Res 2010; 29:141.
37. Siewert JR, Bottcher K, Stein HJ, Roder JD, Busch R. Problem of proximal third gastric carcinoma. World J Surg 1995; 19:523-531.
38. Sakaguchi T, Watanabe A, Sawada H, et al. Characteristics and clinical outcome of proximal-third gastric cancer. J Am Coll Surg 1998; 187:352-357.
39. Yao JC, Tseng JF, Worah S, et al. Clinicopathologic behavior of gastric adenocarcinoma in Hispanic patients: Analysis of a single institution's experience over 15 years. J Clin Oncol 2005; 23:3094-3103.
40. An C, Choi IS, Yao JC, et al. Prognostic significance of CpG island methylator phenotype and microsatellite instability in gastric carcinoma. Clin Cancer Res 2005; 11:656-663.
41. Guan X, Zhao H, Niu J, Tang D, Ajani JA, Wei Q. The VEGF-634G>C promoter polymorphism is associated with risk of gastric cancer. BMC Gastroenterol 2009; 9:77.